Swedish Medtech Phase Holographic Imaging PHI AB (publ) (NGM:PHI) is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.46 SEK | -4.44% |
|
-.--% | +8.39% |
1st Jan change | Capi. | |
---|---|---|
+8.39% | 15.99M | |
-27.34% | 16.26B | |
+13.44% | 1.78B | |
-15.91% | 1.41B | |
+37.40% | 1.29B | |
+5.96% | 836M | |
-30.52% | 807M | |
-38.05% | 708M | |
+27.36% | 611M | |
-27.41% | 590M |
- Stock Market
- Equities
- PHI Stock
- News Phase Holographic Imaging PHI AB
- PHI Aims for US Listing